Multiple Eruptive Facial Tumours in a 72-year-old Man Receiving Pembrolizumab: A Quiz
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0500Keywords:
capillary hemangiomas, immunotherapy, anti-PD1Downloads
References
Chen X, Ma L, Wang X, Mo H, Wu D, Lan B, et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. Cancer Biol Med 2019; 16: 173–181. DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0172
Lin Y, Lin Y, Zhong X, Chen Q, Tang S, Chen J. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient. Front Oncol 2023; 13: 1280208. DOI: https://doi.org/10.3389/fonc.2023.1280208
Sammut SJ, Tomson N, Corrie P. Pyogenic granuloma as a cutaneous adverse effect of vemurafenib. N Engl J Med 2014; 371: 1265–1267. DOI: https://doi.org/10.1056/NEJMc1407683
Groesser L, Peterhof E, Evert M, Landthaler M, Berneburg M, Hafner C. BRAF and RAS mutations in sporadic and secondary pyogenic granuloma. J Invest Dermatol 2016; 136: 481–486. DOI: https://doi.org/10.1038/JID.2015.376
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
